chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report as received from medical assistant refers to a patient of unknown age and gender. On 26-JUL-2012 the patient was vaccinated with first dose of GARDASIL 120 Y (dose unit, route, lot # and expiry date unknown). On 08-SEP-2013 and 13-FEB-2014, patient received second and third dose of GARDASIL respectively. No adverse symptoms reported. The outcome of the patient received GARDASIL on 26-JUL-2012, 09-AUG-2013 and 13-FEB-2014 and no adverse event was unknown. No further information provided. Additional information has been requested.
No adverse event; On 10 May 2023, 27 patients received 0.25ml of the Moderna bivalent vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of UNDERDOSE (On 10 May 2023, 27 patients received 0.25ml of the Moderna bivalent vaccine) and NO ADVERSE EVENT (No adverse event) in an elderly male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 067H22A) for COVID-19 prophylaxis.     It was unknown if patient had acute or chronic long-standing health conditions at the time of vaccination.     On 10-May-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) .25 milliliter. On 10-May-2023, the patient experienced UNDERDOSE (On 10 May 2023, 27 patients received 0.25ml of the Moderna bivalent vaccine). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, UNDERDOSE (On 10 May 2023, 27 patients received 0.25ml of the Moderna bivalent vaccine) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for UNDERDOSE (On 10 May 2023, 27 patients received 0.25ml of the Moderna bivalent vaccine).    No relevant concomitant medications were reported.   Patient was over the age of 65 years.  The vaccine was administered in the deltoid site.   On 11-May-2023, 26 patients were contacted, on 12-May-2023, 18 patients received an additional 0.25ml, 2 patients made appointments to receive the following week and 1 declined to receive the additional 0.25ml dose. A husband and wife pair stated that they would go to the clinic to receive the additional dose but gave no specifics and one patient was mailed a letter as he was not able to be reached by phone.  No treatment medications reported.   This case contains information for the 3rd patient out of 27 patients described by the reporter.
This spontaneous report as received from a physician refers to a 23 years old female patient. The patient's medical history and drug reactions/allergies were not reported. The patient was vaccinated intramuscularly with the first 0.5 ml dose of GARDASIL on 10-OCT-2012. No other co-suspects were reported. No concomitant medications were reported. On 11-OCT-2012 the patient experienced numbness and muscle weakness in right arm, right hand, right shoulder, neck and it was no moving into her right hip and right upper thigh. The patient sought medical attention. At the time of reporting the patient had not recovered. Additional information has been requested.
Patient appeared to experience vasovagal syncope within 30-60 seconds of injection.  Patient briefly lost consciousness  for approximately 30 seconds and complained of severe nausea following the incident.  After recovering, he stated that he has a history of vasovagal syncope and usually receives injections lying down.   He described tingling sensation of hands and feet, nausea, and was perspiring.  Patient had gatorade and water and tried to eat crackers before complaining again of nausea.  Observed him for about 20 minutes at which point he was still complaining of nausea but was able to ambulate unassisted and left with his nurse wife.  Checked in with him three hours later and he stated that he was feeling better.
Left deltoid swollen-firm to touch. Blistered at site - weeping, warm to touch. Tx Benadryl po triple antibiotic ointment and Ibuprofen. Full ROM left arm. Pt complained of itching, no fever. 10 cm x 8 cm induration of tricep left , 6mm uncovered vesicle.
I am reporting this as incidence of pericarditis have been possibly linked. I do not know if this will help or not but I figure more data is important.    2 weeksprior to pericarditis incident I was ill with what I believed to be a cold.  Symptoms persisted and an urgent care prescribed antibiotics.  A week later I had food posioning and was hospitalized for this due to not being able to keep liquids down for the better part of a day.  A few days following this incident I woke early in the morning with chest pain shooting down my arm, not being able to breathe and a dry cough.   When I went to the hospital tests were run and revealed (heart markers?)
Paresthesias("brain zaps"); Dose 1, dose 2: Moderna; dose 3: Pfizer; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): MOD-2021-158733 (Moderna).  A 47-year-old male patient received BNT162b2 (BNT162B2), in Dec2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 47 years for covid-19 immunisation. The patient's relevant medical history included: "Obstructive sleep apnea" (unspecified if ongoing); "Pre-diabetes" (unspecified if ongoing); "Hypertension", start date: 2022 (unspecified if ongoing), notes: Newly diagnosed, gradual onset; "hyperlipidemia" (ongoing); "OCD", start date: 1989 (ongoing), notes: OCD; "Sleep" (ongoing), notes: sleep. Concomitant medication(s) included: ATORVASTATIN oral taken for hyperlipidaemia (ongoing); MELATONIN oral taken for sleep disorder (ongoing); PAROXETINE oral taken for obsessive-compulsive disorder (ongoing); QUETIAPINE oral, stop date: 2021. Vaccination history included: coviD-19/mrna-1273 (DOSE 1, SINGLE; Lot number: 009C21A; Anatomical location: Left arm; Time of administration:11:00; Route of administration:Intramuscular), administration date: 20Apr2021, for COVID-19 immunization, reaction(s): "Brain zaps (paresthesias)"; coviD-19/mrna-1273 (DOSE 2, SINGLE; Lot number: 041C21A; Anatomical location: right arm; Time of administration:06:10; Route of administration:Intramuscular), administration date: 19May2021, for COVID-19 immunization, reaction(s): "Brain zaps (paresthesias)". The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (non-serious) with onset Dec2021, outcome "unknown", described as "Dose 1, dose 2: Moderna; dose 3: Pfizer"; PARAESTHESIA (non-serious), outcome "unknown", described as "Paresthesias("brain zaps")". The event "paresthesias("brain zaps")" required physician office visit.  Additional information: It was reported that allergies to medications, food and other products were unknown. Acute illness at the time of vaccination and up to one month before was none. The symptom was nearly identical to that caused by withdrawal if a dose of paroxetine was skipped. but actually took more than the prescribed dose (to try to make the symptoms go away). Moreover, the patient experienced mild paresthesias (brain zaps) after taking the Pfizer booster in Dec2021; moderate symptoms after taking the bi-valent booster on 14Sep2022 and intolerably severe brain zaps paresthesias on 02Nov2022, the day of onset of a cold-like illness. Patient had not associated such symptoms with the onset of cold or the flu prior to receiving a coronavirus vaccine.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Pain at injection site; Inappropriate schedule of vaccine , patient choice; This case was reported by a pharmacist via call center representative and described the occurrence of injection site pain in a 62-year-old male patient who received Herpes zoster (Shingrix) (batch number BP57E, expiry date 7th December 2021) for prophylaxis.   Previously administered products included Shingrix (received 1st dose greater than 6 months before the date of reporting).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, less than 9 months after receiving Shingrix, the patient experienced injection site pain and drug dose administration interval too long. On an unknown date, the outcome of the injection site pain and drug dose administration interval too long were unknown.   It was unknown if the reporter considered the injection site pain to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received 1st dose of Shingrix somewhere else. The patient experienced pain at injection site after receiving Shingrix. The patient received 2nd dose of Shingrix late than the recommended schedule, which led to lengthening of vaccination schedule. The reporter consented to follow up.
day after vaccine 10/8/21 I woke with a fever and severe body aches these lasted about 48 hours on the 3rd day 10/9/21 I felt better and went out shopping at which time I felt the left side of my face go numb and my speech became garbled, the numbness traveled down my left arm into my left leg which made it hard to walk I had to drag my leg behind me. I was scared I was having a stroke. I was taken to the ER while on the way there my face/arm/leg started to tingle and by the time I arrived at the ER I could not remember my name and my left leg started to shake at first slowly then extremely violently. I was admitted to the hospital for testing and observation and was discharged Sunday 10/11/21
fever up to 102 max 2-3 hr p/inj, high pitched crying;APAP given for fever, crying;
4-5 days p/1st dose of vax recvd pt exp diffuse macular circular plaques appearing 1/2 cm to cm in diameter; also erythematous w/white scaly center; no pain little pruritis;
Morning after Vaccine 1 (pain and swelling) for two days. Could not use arm.       Morning after Vaccine 2 ( pain and swollen in left arm . Could not even lift arm. Chills, Extreme weakness, fever and felt like I had a cold /congestion. All this for two days. Third day, felt still like a cold and weakness. Site still swollen , but better.
At 11pm started having chills, by 12pm was shivering uncontrollably and my body was involuntarily stretching as i woke up to add more covers, as in the whole body morning kind of stretching,  this continued for maybe an hour. VERY  weird.  Drank about 30 fl oz of water, very dehydrated. Then around 1:30 pm  my body became so hot, got a headache, flu like pain l thru my body and joints, nausea and skin sensitivity , kidney area is very painful and sensitive which continues now at 4:00 pm. Eyes are completely blood shot and ache to move them . Did not take any medication or NSAIDS, just tried to rest and sleep all day.
Patient appeared nervous/anxious prior to vaccine. Shortly after administration, patient got up and felt nausea and vomited 5-8 minutes after receiving vaccine.
Pneumovax vaccination occurred 7/18/06 at 4pm.  There was immediate pain with injection of Pneumovax.  Pain worsened as the day progressed and peaked for next 48 hours.  Injection was administered in left shoulder.  All of left upper extremity was painful/tender to palpation.  Erythema and edema of left deltoid occurred appx 12 hours later.  Fever started appx 30 hours after injection with a max temp of 101deg F.  I was evaluated by another physician at another clinic and was started on Avelox 400mg one tab by mouth once per day for 7 days due to cellulitis infection of left deltoid.  3 days post injection, site is still erythematous, appx 10cm in diameter, edematous, and painful.  Symptoms are somewhat alleviated by NSAIDS.  I tried to alert the healthcare system today to let them know about the reaction, but was unsuccessful.
pt recv vax & exp severe pain & inability to lift/move rt arm (pain is deep inside shoulder w/muscle cramps) 3-4wk p/vax;pt to ER because of pain & muscle spasms;cellulitis & back pain also;pt unable to perform nl functions;
This spontaneous report was received from a physician via company representative refers to a 60 year old female patient. On an unknown date in January 2014, the patient was vaccinated with ZOSTAVAX standard dose. On an unknown date in January 2014 (also reported as 2-3 weeks ago), the patient experienced ophthalmic shingles. The patient sought medical attention and visited the physician office for treatment. The patient was treated with VALTREX. The outcome of the event ophthalmic shingles was unknown. The reporter did not provide the causality between the event and the suspect drug. Additional information has been requested.
This spontaneous report was received from a pharmacist refers to a 30 year old patient of an unknown gender. The patient's concurrent conditions, medical history, drug reactions, allergies and concomitant medications were not reported. On an unknown date, the patient was vaccinated with first dose of GARDASIL 9 (dose, units, frequency and route not reported) (lot # and expiration date not reported). On an unspecified date, it was reported that, patient received second dose of GARDASIL 9 at an unspecified location (inappropriate dose of vaccine administered). No adverse effects were reported and no additional information was provided. No product quality complaint was involved.
Headache, malaise, arthralgia beginning 12 hours after vaccine. Fever (ranging from 100.3 to 100.9) beginning 16 hours after vaccine. 36 hours after vaccine, headache, malaise, and arthralgia remain; fever subsided 32 hours after vaccine.
The same night as the second dose of Pfizer vaccine i was experiencing fever of 101.8 with chills,sweats, full body aches, migraine,  nausea, stomach pain ,lower back pain and diarrhea for 4 days (01/27/2021 @11:45pm till 01/31/2021 pm)
12hr p/vax lt arm became swollen, painful w/some hand numbness for 2 days;t102 orally 19FEB-20FEB97;
Information has been received from a physician concerning a 11 year old female with pertinent medical history reported as none who on 16-JUL-2007 was vaccinated with a first dose of GARDASIL (lot # not reported). There was no concomitant medication. On approximately 16-JUL-2007 the patient developed a "rash" at the injection site following her initial GARDASIL dose 2 years ago. The "rash" persisted for several months. It was described as a 1 and 1/2 inch raised area with small dots and itching. Patient self treated with ibuprofen and hydrocortisone. The father of the patient sent a letter to the pediatrician who gave the vaccine with a drawing of the arm and rash. Patient was not seen in the office for the rash only advised to try hydrocortisone by phone nurse at the office. On an unspecified date the patient recovered. There were no laboratories diagnostics studies performed. Follow up information has been received from a physician who reported the patient received the first dose of GARDASIL in a different office in 2007. On the same day patient received a dose of MENACTRA and dose of DTaP (lot # and injection site not reported). The patient developed itchy and rash at the site of GARDASIL. The physician did not believe the rash was examined by the physician. Unspecified laboratories were done. The physician want to know if she should have second and third dose of GARDASIL. This one of two reports from the same source. Additional information has been requested.
infant patient received a dose of kinrix; This case was reported by a other health professional and described the occurrence of inappropriate age at vaccine administration in a 4-month-old male patient who received DTPa-IPV (Kinrix) (batch number E2L54, expiry date 3rd March 2023) for prophylaxis.   Co-suspect products included dtpa-ipv vaccine pre-filled syringe device (Kinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 13th October 2021, the patient received Kinrix and Kinrix Pre-Filled Syringe Device. On 13th October 2021, unknown after receiving Kinrix and Kinrix Pre-Filled Syringe Device, the patient experienced inappropriate age at vaccine administration. On an unknown date, the outcome of the inappropriate age at vaccine administration was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The infant patient received a dose of Kinrix, which led to inappropriate age at vaccine administration.  The event was reported to VAERS, according to the reporter. Lot number was from the Salesforce GlaxoSmithKline database.  The reporter consented to follow up. Follow up via email was okay.
pt recvd vax & felt dizzy-fell into wall & slid to floor-very pale-VS OK awakened easily w/ammounia spirits;
Fatigue, appears to be due  decreased heart rate.  Resting heart rate declined approximately 10 BPM between 12/7/2021 and 12/9/2021.  This was detected with a fitness tracker and confirmed with another tracked, a finger OX/BP meter and cuff BP meter over the course of multiple weeks.   Condition resolved after approximately 3 weeks and treatment with NSAIDS.  Dr said Bradycardia was likely due to Pericarditis.
Initial report was received 24 October 2011 from a health care professional, who is also the patient. A female patient (age and date of birth not reported) who had a history of Celiac disease and severe chest pain, had received an injection of INFLUENZA VACCINE (manufacturer unknown, lot number, route and site of administration not reported) on 19 October 2011 and several hours after vaccination, she developed a severe Celiac reaction consisting of severe chest pain which lasted more than 36 hours. The patient also had to take time off from work. The patient had not altered anything in her diet or what she had touched (the patient also has a history of reacting to tactile gluten) on the day of vaccination. According to the patient, their reaction to any gluten product consists of severe chest pain that could last anywhere from 24 to 96 hours. The patient's son also had a history of Celiac disease. Outcome was not reported. The reporter for this case is the same as for case number 2011-10377. Documents held by sender: None.
Headache; fatigue; This is a spontaneous report from a contactable female consumer. A patient of an unspecified age and gender received BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot number- UNKNOWN) via an unspecified route of administration as unknown single dose for COVID-19 immunization. Patient medical history and concomitant medications were not reported. Patient experienced headache and fatigue after the use of the product. The outcome of the events was unknown.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
10 minutes after receiving the first dose of moderna vaccine, patient started to not feel well. She received 50 mg of benadryl, which she then threw up.  After that, her throat broke out into hives, and her eyes swelled shut. Then she received 2 doses of epinephrine via auto injector, and she was able to breath after that.  An ambulance came and took her to the emergency room
On 04/2021 in the morning I had shortness of breath and cough, chest pain. After 2 days I went to see a nurse at my doctors office who told me that I was experiencing allergies. She prescribed me with an inhaler, and steroids. After 2 weeks I went back again because I was using the inhaler too much. I had a reactive air way. They did a chest X-ray. It showed that there was a spot in my lung. Then they send me over to the ER for chest tubes. On 02/2023 I experienced chest pain and tightness in my chest they did surgery and trimmed the spot that I had in my chest. The procedure called Pleurodesis. Now I am recovered fully.
has been suffering from shooting arm pain that extends to the fingers; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of pain in arm in a 65-year-old female patient who received Herpes zoster (Shingrix) (batch number 2hc4l, expiry date 09-JUL-2024) for prophylaxis.  On 12-APR-2023, the patient received the 2nd dose of Shingrix. On 12-APR-2023, less than a day after receiving Shingrix, the patient experienced pain in arm (Verbatim: has been suffering from shooting arm pain that extends to the fingers). The outcome of the pain in arm was unknown.  It was unknown if the reporter considered the pain in arm to be related to Shingrix.  It was unknown if the company considered the pain in arm to be related to Shingrix.  Additional Information: GSK Receipt Date: 05-JUN-2023 Information about event, vaccine and patient provided. The vaccine administration facility was the same as primary reporter. The reporter consented to follow-up.
I had pain at the injection site for 24 hours. On 06/16/2022, I tested positive for COVID-19 after going on vacation with my family.  I tested with a home test and PCR test at doctors office.  I was given the prescription Paxlovid. I took the whole course of medication and I rebound. I had upper respiratory issues which caused me to cough.  I tested everyday up to 06/28/2022 and was still positive. Finally I tested negative on 07/06/2022. I was given a prescription for cough medicine with codeine and a steroid which helped relieve the cough and let me sleep. I also had a terrible time with being restless and my blood pressure went up. I had never had problems with my blood pressure but no I take medication to control it.
Patient was administered 0.5mL Alfuria vaccine which is more than the recommended amount of 0.25mL. Patient monitored post vaccination for adverse reactions. Patient did not report any symptoms after the vaccine. Patient left site with mother as patient felt good as per mom.
HCP reports no further AE's; inadvertent administration of PROQUAD instead of MMR II; inadvertent administration of PROQUAD instead of MMR II; This spontaneous report was received from a nurse and refers to a 17-year-old male patient. The patient's medical history and concurrent conditions were not reported. Concomitant medications included varicella virus vaccine live (oka/merck) (VARIVAX) and multiple other vaccines (unspecified).  On 23-MAR-2022, the patient was inadvertently vaccinated with a dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA) (PROQUAD) subcutaneous injection, 0.5 milliliter, lot #U029325, expiration date: 19-MAR-2023, reconstituted with sterile diluent administered for prophylaxis (strength, and route of administration were not provided) (product administered to patient of inappropriate age) instead of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (wrong product administered). Vaccines were administered. No further adverse events (AE's) were reported.
Information has been received from a physician concerning a 74 year old female who on an unknown date, was vaccinated with a dose of PNEUMOVAX 23 (Lot#664653/1337Y). On an unknown date, the patient had increased redness and pain at the injection site. There was no lab diagnostics studies performed. At the time of the report, the outcome were unknown. The patient did not seek medical attention. No further information is available.
At  6:03 PM, Client stated that he felt a warm feeling in both feet.  He stated that numbness and tingling he had in his feet was not new.  Reported that this is a S/E from the medication Mitazopine that he takes at night.  Client stated that his feet feel better after he removed his socks and lifted up his feet.  Client instructed to go to ER if he felt worse.  He said he would if the symptoms of warming feeling returned.